Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer’s Proteograph® ...

Seer (NASDAQ:SEER) reported lower first-quarter revenue but reaffirmed its full-year 2026 outlook, with management pointing ...

Hi. My name is Yuko Oku and I'm part of the life science tools and diagnostics team at Morgan Stanley. Before we begin, I'd like to remind our listeners that ...

Good day, and thank you for standing by. Welcome to Seer first quarter 2025 earnings conference call. At this time all participants are in a listen-only mode. After the speaker's presentation, there ...